Claims for Patent: 7,709,467

Summary for Patent: 7,709,467

Title:	Apoptosis promoters
Abstract:	Compounds which inhibit the activity of anti-apoptotic family protein members, compositions containing the compounds and methods of treating diseases during which occur expression one or more than one of an anti-apoptotic family protein member are disclosed.
Inventor(s):	Bruncko; Milan (Green Oaks, IL), Ding; Hong (Gurnee, IL), Elmore; Steven W. (Northbrook, IL), Kunzer; Aaron R. (Schaumburg, IL), Lynch; Christopher L. (Trevor, WI), McClellan; William J. (Waukegan, IL), Park; Cheol Min (Gurnee, IL), Song; Xiahong (Grayslake, IL), Wang; Xilu (Grayslake, IL)
Assignee:	Abbott Laboratories (Abbott Park, IL)
Application Number:	12/120,914
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 7,709,467
Patent Claims:	1. A method of treating patient with a lymphoid malignancy of B-cell origin or a small cell lung cancer, the method comprising administering to said patient a therapeutically effective amount of a compound having formula (II) ##STR00027## wherein X.sup.3 is Cl or F; X.sup.4 is azepan-1-yl, morpholin-1-yl, 1,4-oxazepan-4-yl, pyrrolidin-1-yl, N(CH.sub.3).sub.2, N(CH.sub.3)(CH(CH.sub.3).sub.2), 7-azabicyclo[2.2.1]heptan-1-yl or 2-oxa-5-azabicyclo[2.2.1]hept-5-yl, and R.sup.0 is ##STR00028## wherein X.sup.5 is CH.sub.2, C(CH.sub.3).sub.2 or CH.sub.2CH.sub.2; X.sup.6 and X.sup.7 are both hydrogen or are both methyl; and X.sup.8 is F, Cl, Br or I; or X.sup.4 is azepan-1-yl, morpholin-1-yl, pyrrolidin-1-yl, N(CH.sub.3)(CH(CH.sub.3).sub.2) or 7-azabicyclo[2.2.1]heptan-1-yl, and R.sup.0 is ##STR00029## X.sup.4 is N(CH.sub.3).sub.2 or morpholin-1-yl, and R.sup.0 is ##STR00030## 2. The method of claim 1, wherein the compound having formula (II) is N-(4-(4-((2-(4-chlorophenyl)-5,5-dimethyl-1-cyclohex-1-en-1-yl)methyl)pip- erazine-1-yl)benzoyl)-4-(((1R)-3-(morpholin-4-yl)-1-((phenylsulfanyl)methy- l)propyl)amino)-3-((trifluoromethyl)sulfonyl)benzenesulfonamide. 3. The method of claim 1, wherein the compound is orally administered to the patient. 4. The method of claim 1, wherein the patient has a small cell lung cancer. 5. The method of claim 1, wherein the patient has a lymphoid malignancy of B-cell origin. 6. The method claim 5, wherein the lymphoid malignancy of B-cell origin is a non Hodgkin's lymphoma. 7. The method of claim 5, wherein the lymphoid malignancy of B-cell origin is a follicular lymphoma. 8. The method of claim 5 further comprising administering a therapeutically acceptable amount of etoposide to the patent. 9. The method of claim 5 further comprising administering a therapeutically acceptable amount of vincristine to the patent. 10. The method of claim 5 further comprising administering a therapeutically acceptable amount of rituximab to the patent.

Details for Patent 7,709,467

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Genentech, Inc.	RITUXAN	rituximab	Injection	103705	11/26/1997		2025-05-12
Idec Pharmaceuticals Corp.	RITUXAN	rituximab	Injection	103737	02/19/2002		2025-05-12
Genentech, Inc.	RITUXAN HYCELA	rituximab and hyaluronidase human	Injection	761064	06/22/2017		2025-05-12